Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Gross Profit: 2017-2025

Historic Gross Profit for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $42.3 million.

  • Puma Biotechnology's Gross Profit fell 17.77% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.0 million, marking a year-over-year decrease of 3.39%. This contributed to the annual value of $166.1 million for FY2024, which is 3.98% down from last year.
  • Latest data reveals that Puma Biotechnology reported Gross Profit of $42.3 million as of Q3 2025, which was up 5.40% from $40.1 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Gross Profit registered a high of $70.8 million during Q4 2022, and its lowest value of $33.0 million during Q1 2024.
  • For the 3-year period, Puma Biotechnology's Gross Profit averaged around $41.5 million, with its median value being $42.3 million (2025).
  • The largest annual percentage gain for Puma Biotechnology's Gross Profit in the last 5 years was 62.92% (2022), contrasted with its biggest fall of 49.15% (2022).
  • Quarterly analysis of 5 years shows Puma Biotechnology's Gross Profit stood at $43.5 million in 2021, then surged by 62.92% to $70.8 million in 2022, then plummeted by 32.42% to $47.9 million in 2023, then decreased by 5.64% to $45.2 million in 2024, then declined by 17.77% to $42.3 million in 2025.
  • Its Gross Profit was $42.3 million in Q3 2025, compared to $40.1 million in Q2 2025 and $35.5 million in Q1 2025.